相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Susceptibility of Highly Pathogenic H5N1 Influenza Viruses to the Neuraminidase Inhibitor Oseltamivir Differs In Vitro and in a Mouse Model
Elena A. Govorkova et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States
Nila J. Dharan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation
Aeron C. Hurt et al.
JOURNAL OF VIROLOGY (2009)
Medical management of influenza infection
Anne Moscona
ANNUAL REVIEW OF MEDICINE (2008)
Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in Mice
Natalia A. Ilyushina et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes
Yacine Abed et al.
ANTIVIRAL RESEARCH (2008)
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants
Patrick J. Collins et al.
NATURE (2008)
Update on Avian Influenza A (H5N1) Virus Infection in Humans
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo
Hui-Ling Yen et al.
JOURNAL OF VIROLOGY (2007)
Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus
Elena A. Govorkova et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes
A. C. Hurt et al.
ANTIVIRAL RESEARCH (2007)
Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir
M. A. Rameix-Welti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
Rupert J. Russell et al.
NATURE (2006)
Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model
Taronna R. Maines et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection
MP Malakhov et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Brief report - Oseltamivir resistance during treatment of influenza A (H5N1) infection
MD de Jong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice
HL Yen et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Confronting the avian influenza threat: vaccine development for a potential pandemic
I Stephenson et al.
LANCET INFECTIOUS DISEASES (2004)
Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir
J McKimm-Breschkin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo
JAL Ives et al.
ANTIVIRAL RESEARCH (2002)
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo
J Carr et al.
ANTIVIRAL RESEARCH (2002)
Universal primer set for the full-length amplification of all influenza A viruses
E Hoffmann et al.
ARCHIVES OF VIROLOGY (2001)
分享论文
